What Clinicians Want to Know About the Management of Relapsed/Refractory Mantle Cell Lymphoma
Hematologic Oncology Update
New Trials and Phase 1/2 Data in the Management of Relapsed/Refractory Mantle Cell Lymphoma
This chapter explores two trials comparing BR to Zanu retuximab in the management of mantle cell lymphoma, discussing response rates, toxicity, and selectivity of the drugs.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
